Botulinum toxin in the treatment of recalcitrant mutational dysphonia.
Mutational falsetto is the failure of the normal drop in vocal pitch at puberty. Voice therapy almost always achieves an appropriate pitch; however, in cases of failure, surgical treatment has also been recommended. We report a case of a 47-year-old man with an above-average fundamental frequency and a thin voice quality in the absence of any signs of androgen insufficiency. Laryngeal examination revealed atrophy of the vocalis muscle. Voice therapy was unsuccessful in achieving a stable voice. Injection of 15 units of botulinum toxin into each cricothyroid muscle initially resulted in aphonia, but the voice returned by 1 week. Average fundamental frequency was 84 Hz at 1 week, 104 Hz at 1 month, and 100 Hz at 1 year. We hypothesize that mutational dysphonia is an habitual dysfunction of the voice with inappropriate activation of the cricothyroid muscle and disuse of laryngeal adductor muscles. Temporary deactivation of the cricothyroid muscle enforces adoption of a more appropriate vocal mechanism. Botulinum toxin as an adjunct to voice therapy should be considered before surgical alteration of the glottis in patients with recalcitrant mutational falsetto.
College of Medicine, University of Tennessee, Memphis.
G E
GE
Woodson
T
T
Murry
D001905:Botulinum Toxins / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010700:Phonetics; D016896:Treatment Outcome; D014827:Vocal Cords / Q000503:physiopathology*; D014832:Voice Disorders / Q000188:drug therapy* / Q000503:physiopathology*; D014833:Voice Quality
D001905:Botulinum Toxins